Opaleye Management as of Dec. 31, 2022
Portfolio Holdings for Opaleye Management
Opaleye Management holds 40 positions in its portfolio as reported in the December 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 19.4 | $56M | 3.8M | 14.76 | |
| Tela Bio (TELA) | 8.3 | $24M | 2.1M | 11.50 | |
| Rhythm Pharmaceuticals (RYTM) | 7.4 | $21M | 735k | 29.12 | |
| Ocular Therapeutix (OCUL) | 5.9 | $17M | 6.1M | 2.81 | |
| Crinetics Pharmaceuticals In (CRNX) | 4.7 | $13M | 732k | 18.30 | |
| Cytokinetics Com New (CYTK) | 4.0 | $12M | 250k | 45.82 | |
| Keros Therapeutics (KROS) | 4.0 | $11M | 238k | 48.02 | |
| Vaxcyte (PCVX) | 3.0 | $8.5M | 177k | 47.95 | |
| Biohaven (BHVN) | 2.6 | $7.5M | 540k | 13.88 | |
| 4d Molecular Therapeutics In (FDMT) | 2.5 | $7.3M | 330k | 22.21 | |
| Protara Therapeutics Com Stk (TARA) | 2.5 | $7.2M | 2.7M | 2.68 | |
| Tracon Pharmaceuticals Com New | 2.4 | $6.8M | 4.6M | 1.49 | |
| Larimar Therapeutics (LRMR) | 2.2 | $6.4M | 1.6M | 4.13 | |
| Kalvista Pharmaceuticals (KALV) | 2.2 | $6.2M | 923k | 6.76 | |
| Eton Pharmaceuticals (ETON) | 2.1 | $6.1M | 2.2M | 2.82 | |
| Edgewise Therapeutics (EWTX) | 1.9 | $5.5M | 611k | 8.94 | |
| Proqr Therapeutics Nv Shs Euro (PRQR) | 1.9 | $5.4M | 1.5M | 3.70 | |
| Phathom Pharmaceuticals (PHAT) | 1.6 | $4.7M | 418k | 11.22 | |
| Xoma Corp Del Com New (XOMA) | 1.6 | $4.5M | 243k | 18.40 | |
| Codexis (CDXS) | 1.6 | $4.5M | 958k | 4.66 | |
| Urogen Pharma (URGN) | 1.5 | $4.3M | 489k | 8.87 | |
| Karyopharm Therapeutics | 1.5 | $4.3M | 1.2M | 3.55 | |
| Astria Therapeutics (ATXS) | 1.4 | $3.9M | 262k | 14.89 | |
| Liquidia Corporation Com New (LQDA) | 1.2 | $3.6M | 560k | 6.37 | |
| Zentalis Pharmaceuticals (ZNTL) | 1.2 | $3.4M | 168k | 20.14 | |
| Marinus Pharmaceuticals Com New | 1.1 | $3.3M | 826k | 3.98 | |
| Edap Tms S A Sponsored Adr (EDAP) | 1.1 | $3.3M | 307k | 10.66 | |
| Aadi Bioscience (WHWK) | 1.1 | $3.2M | 252k | 12.83 | |
| Morphosys Sponsored Ads (MOR) | 1.1 | $3.2M | 897k | 3.58 | |
| Mersana Therapeutics | 0.9 | $2.7M | 460k | 5.86 | |
| Theseus Pharmaceuticals | 0.9 | $2.7M | 535k | 4.98 | |
| Fennec Pharmaceuticals (FENC) | 0.9 | $2.6M | 272k | 9.60 | |
| Ideaya Biosciences (IDYA) | 0.9 | $2.5M | 139k | 18.17 | |
| Stereotaxis Com New (STXS) | 0.9 | $2.5M | 1.2M | 2.07 | |
| Bioatla (BCAB) | 0.8 | $2.2M | 262k | 8.25 | |
| Fortress Biotech | 0.5 | $1.3M | 2.1M | 0.66 | |
| Allakos | 0.4 | $1.3M | 154k | 8.42 | |
| Theravance Biopharma (TBPH) | 0.3 | $983k | 88k | 11.22 | |
| Trevi Therapeutics (TRVI) | 0.3 | $936k | 485k | 1.93 | |
| Modular Medical Com New (MODD) | 0.2 | $490k | 245k | 2.00 |
